Roche Holding AG (FRA:RHO5)
Germany · Delayed Price · Currency is EUR | Market Cap | 284.35B +11.0% |
| Revenue (ttm) | 68.05B +1.5% |
| Net Income | 13.83B +55.6% |
| EPS | 17.23 +55.6% |
| Shares Out | n/a |
| PE Ratio | 20.55 |
| Forward PE | 15.87 |
| Dividend | 10.85 (3.06%) |
| Ex-Dividend Date | Mar 12, 2026 |
| Volume | 91 |
| Open | 358.95 |
| Previous Close | 356.85 |
| Day's Range | 353.05 - 358.95 |
| 52-Week Range | 259.15 - 411.60 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 24, 2026 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir... [Read more]
Financial Performance
In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.
Financial numbers in CHF Financial StatementsNews
FDA Grants Priority Review For Roche's NDA For Giredestrant In Breast Cancer
(RTTNews) - Roche Holding AG (RHHBY), a healthcare company, reported that its New Drug Application seeking approval for Giredestrant as an adjuvant treatment for patients with stage I-III ER+/HER- bre...
Roche Announces FDA's Filing Acceptance Under Priority Review For Giredestrant
(RTTNews) - Roche (RHHBY, RO.SW, ROG.SW) announced the FDA has accepted the company's New Drug Application under Priority Review for giredestrant, an investigational oral selective oestrogen receptor ...
FDA Accepts New Drug Application for Genentech's Giredestrant in ER-Positive Early-Stage Breast Cancer, the First and Only Oral SERD With Positive Phase III Results in the Curative Setting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $RHHBY--FDA accepts NDA for Genentech's giredestrant in ER+ early-stage breast cancer.
FDA accepts New Drug Application for Roche's giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting
Basel, 02 June 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the United States (US) Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) under Prio...
Genentech Presents Updated Clinical Results Of Enicepatide And Petrelintide At ADA 2026
(RTTNews) - Genentech, a biotechnology company and member of the Roche group (RHHVF), announced that it will present new clinical data for Enicepatide and Petrelintide from its obesity portfolio to ad...
Louth GAA FL Division 2 Round-up: Walsh in sizzling form for Fechins as Roche sit top
Roche to present new data advancing its obesity portfolio at the American Diabetes Association's 2026 Scientific Sessions
Basel, 1 June 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that new data from its obesity portfolio will be presented at the 2026 Scientific Sessions of the American Diabetes Association®...
Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association's 2026 Scientific Sessions
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that new data from its obesity portfolio will be presented at the 202...
Roche Launches Liver Disease Panel To Help Clinicians Identify Risk Earlier
(RTTNews) - Roche (RHHBY, RO.SW, ROG.SW) announced the launch of its Liver Disease Panel, a suite of certified algorithms including the CE-marked algorithm LiverPRO, to support better-informed clinica...
Louth GAA FL Div 2 Round-up: Roche remain top after seeing off O’Raghallaighs
Roche Emmets 2-19 O’Raghallaighs 1-15
Genentech to Present New Data at ASCO 2026, Reinforcing Giredestrant's Potential to Transform the Treatment Paradigm in Early Breast Cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), will present new data from nine approved and investigational medicines across more th...
Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer
Basel, 19 May 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) will present new data from nine approved and investigational medicines across more than 15 indications at the 2026 American Society of Clinical ...
Roche, Medicines Patent Pool sign deal to expand access to influenza drug
Roche and the Medicines Patent Pool have signed a licensing agreement to expand access to the Swiss drugmaker's flu drug, Xofluza, in low- and middle-income countries, the organizations said on Monda...
FDA Approves Genentech's Tecentriq for Adjuvant Muscle-Invasive Bladder Cancer With ctDNA-Guided Treatment
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentr...
Roche's Diagnostics Day 2026 Transcript
Roche's Diagnostics Day 2026 Transcript
Roche gets European approval for Alzheimer’s diagnosis blood test
Swiss pharmaceutical company Roche has received European approval for a blood test that can detect and rule out Alzheimer’s disease, offering a simpler and less invasive alternative to current diagnos...
Roche gets second European approval for Alzheimer's test
Swiss drugmaker Roche has received the CE mark - a European regulatory clearance allowing sale in the region - for its second Elecsys blood test for Alzheimer's disease, it said on Tuesday.
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Basel, 12 May 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has received CE Mark for Elecsys® pTau217, a blood test developed in collaboration with Eli Lilly and Company and design...
Roche (RHHBF) to Acquire PathAI for $1.1B to Enhance Digital Pathology Services
Roche (RHHBF) to Acquire PathAI for $1.1B to Enhance Digital Pathology Services
Roche Acquires PathAI for $750 Million, Stock Impact Expected
Roche Acquires PathAI for $750 Million, Stock Impact Expected
Roche Enters $750 Mln Merger Deal To Acquire PathAI To Expand AI-Driven Diagnostics
(RTTNews) - Roche (RHHBY), a healthcare company, announced on Thursday that it has entered into a definitive merger agreement to acquire PathAI, a digital, AI-powered technology firm serving pathology...
Roche to Buy PathAI for Up to $1.05 Billion to Bolster AI Diagnostics Tools
The deal seeks to bolster the artificial-intelligence offerings of Roche's diagnostics division, helping to accelerate clinical-therapy development.
Switzerland's Roche agrees to acquire US-based PathAI
Swiss pharmaceutical giant Roche said on Thursday it had agreed to acquire U.S.-based digital pathology and AI-powered technology firm PathAI in a deal worth $750 million upfront plus further miles...
Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics
Basel, 7 May 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that it has entered into a definitive merger agreement to acquire PathAI, a US-based company in digital pathology and AI-powered...
The Zacks Analyst Blog Highlights Microsoft, Bank of America, Roche and GSI Technology
Microsoft faces pressure from capacity constraints and competition, even as AI momentum and Azure growth drive demand beyond available supply.